Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc. (Nasdaq: ENSC) is a clinical-stage pharmaceutical company focused on developing abuse-deterrent and overdose-resistant drug candidates targeting opioid and stimulant therapies. The company filed a Form 10-Q with the Securities and Exchange Commission on August 7, 2020, offering a periodic update on its financial condition and development activities. Ensysce operates in the life sciences and specialty pharmaceuticals sector and reached the public markets through a SPAC transaction, with Leisure Acquisition Corp. serving as the vehicle that brought the company public. The filing reflects the company's status as a development-stage entity advancing its proprietary drug-formulation pipeline. For full filing history, deal timelines, and ownership analytics on ENSC, sign up for complete data on SpacDesk.